Tempest Appoints Andrew Fang to Spearhead Business Development, Focus on Global Licensing and Phase 3 Asset Partnerships
summarizeSummary
Tempest Therapeutics has appointed Andrew Fang, Ph.D., as its new Head of Business Development. This strategic hire is critical for the company, which recently disclosed a 'going concern' warning and has engaged in significant share resale filings. Dr. Fang's mandate is to advance strategic partnerships, cross-border licensing, and corporate transactions, with a particular focus on securing a partner for its Phase 3-ready amezalpat program and expanding its CAR-T portfolio, especially in China. This move signals a proactive effort to secure non-dilutive funding and accelerate pipeline development, which is vital for the company's financial health and strategic pivot. Investors will be closely watching for any partnership announcements that could emerge from this appointment.
في وقت هذا الإعلان، كان TPST يتداول عند ٢٫١٧ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٣٠٫٧ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ١٫٥٠ US$ و١٢٫٢٣ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٧ من 10. المصدر: GlobeNewswire.